KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Research & Development (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Research & Development for 18 consecutive years, with $210.2 million as the latest value for Q1 2026.

  • For Q1 2026, Research & Development rose 4.69% year-over-year to $210.2 million; the TTM value through Mar 2026 reached $925.0 million, up 4.16%, while the annual FY2025 figure was $915.6 million, 1.56% up from the prior year.
  • Research & Development hit $210.2 million in Q1 2026 for Ionis Pharmaceuticals, down from $279.6 million in the prior quarter.
  • Across five years, Research & Development topped out at $279.6 million in Q4 2025 and bottomed at -$444.9 million in Q4 2022.
  • Average Research & Development over 5 years is $176.9 million, with a median of $215.3 million recorded in 2023.
  • Year-over-year, Research & Development surged 157.67% in 2023 and then decreased 6.28% in 2025.
  • Ionis Pharmaceuticals' Research & Development stood at -$444.9 million in 2022, then soared by 157.67% to $256.6 million in 2023, then decreased by 4.31% to $245.5 million in 2024, then grew by 13.91% to $279.6 million in 2025, then dropped by 24.84% to $210.2 million in 2026.
  • According to Business Quant data, Research & Development over the past three periods came in at $210.2 million, $279.6 million, and $217.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.